肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响*

doi:10.3969/j.issn.1672-5069.2021.04.025

摘要/Abstract

摘要： 目的研究肝细胞癌癌组织色素框同源蛋白7(CBX7)和磷酸化胞外信号调节激酶(PERK)表达及其对术后预后的影响。方法 2016年1月～2017年1月在我院接受治疗的肝细胞癌患者68例,所有患者接受肝癌切除术,并随访3年。术后,取癌组织和癌旁肝组织,采用RT-PCR法检测癌组织和癌旁组织CBX7 mRNA和PERK mRNA水平,采用免疫组化法检测癌组织CBX7和PERK蛋白表达。结果癌组织CBX7 mRNA水平为(0.51±0.10),显著低于癌旁组织【(4.11±0.91),P<0.05】,而癌组织PERK mRNA水平为(4.87±0.99),显著高于癌旁组织【(0.58±0.15,P<0.05】;38例肿瘤直径>3 cm患者癌组织CBX7蛋白呈高表达阳性率为33.3%,显著低于30例肿瘤直径≤3 cm组的66.7%,而PERK高表达阳性率为73.3%,显著高于肿瘤直径≤3 cm组的26.7%,28例AJCC Ⅲ/Ⅳ期患者癌组织CBX7蛋白呈高表达阳性率为8.3%,显著低于40例AJCC Ⅰ/Ⅱ期患者的91.7%,而PERK高表达阳性率为70.0%,显著高于对照组的30.0%(P<0.05);32例癌组织CBX7高表达患者1 a、2 a和3 a生存率分别为78.1%、65.6%和53.1%,显著高于36例呈低表达患者【分别为52.7%、38.9%和30.6%,P<0.05】,38例癌组织PERK高表达患者1 a、2 a和3 a生存率分别为55.3%、44.7%和31.6%,显著低于30例呈低表达患者【分别为80.0%、63.6%和53.3%,P<0.05】。结论癌组织CBX7表达下调,而PERK表达增强的HCC患者预后差,需要给予特别的关注。

关键词: 肝细胞癌, 色素框同源蛋白7, 磷酸化胞外信号调节激酶, 预后

Abstract: Objective The aim of this study was to detect the expression of chromobox protein homolog 7 (CBX7) and phosphorylated extracellular signal-regulated kinase (PERK) in cancerous tissues in patients with hepatocellular carcinoma (HCC) and explore their implications of prognosis after hepatectomy. Methods A total of 68 patients with HCC were treated with hepatectomy in our hospital between January 2016 and January 2017, and the cancerous and adjacent non-cancerous liver tissues were collected. The CBX7 mRNA and PERK mRNA were detected by RT-PCR, and the expression of CBX7 and PERK proteins in cancerous tissues were detected by immunohistochemistry. Results The CBX7 mRNA level in cancerous tissue was significantly lower than that in adjacent liver tissues [(0.51±0.10) vs. (4.11±0.91), P<0.05], while the PERK mRNA level was significantly higher than that in adjacent liver tissues [(4.87±0.99) vs. (0.58±0.15, P<0.05]; the positive rate of intensified expression of CBX7 in 38 patients with tumor diameter >3 cm was 33.3%, significantly lower than 66.7% in 30 patients with tumor size ≤3 cm, while the positive rate of intensified expression of PERK was 73.3%, much higher than 26.7% in patients with tumor size ≤3 cm; the positive rate of intensified expression of CBXY in 28 patients with AJCC stage Ⅲ/Ⅳ was 8.3%, significantly lower than 91.7% in 40 patients with AJCC stage Ⅰ/Ⅱ, while the positive rate of intensified expression of PERK was 70.0%, significantly higher than 30.0%(P<0.05) in the control; the 1 a, 2 a and 3 a survival rates in 32 patients with cancerous intensified expression of CBX7 were 78.1%, 65.6% and 53.1%, significantly higher than 52.7%, 38.9% and 30.6% (P<0.05) in 36 patients with weak or negative expression, and the 1 a, 2 a and 3 a survival rates in 38 patients with cancerous intensified expression of PERK were 55.3%, 44.7% and 31.6%, significantly lower than 80.0%,63.6% and 53.3% (P<0.05) in 30 patients with weak or negative expression. Conclusion The HCC patients with decreased cancerous expression of CBX7 and intensified expression of PERK might have a poor prognosis after hepatectomy, which should take into consideration in dealing with them in clinical practice.

Key words: Hepatocellular carcinoma, Chromobox protein homolog 7, Phosphorylated extracellular signal-regulated kinase, Prognosis

王婷婷, 辛洋, 王娜娜. 肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响^*[J]. 实用肝脏病杂志, 2021, 24(4): 552-555.

Wang Tingting, Xin Yang, Wang Nana. Expression of CBX7 and PERK incancerous tissues in patients with hepatocellular carcinoma and its implication of prognosis after hepatectomy[J]. Journal of Practical Hepatology, 2021, 24(4): 552-555.

参考文献

[1] Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1):7-30.
[2] Dhanasekaran R, Gabay-Ryan M, Baylot V, et al. Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget, 2017, 9(5):5517-5528.
[3] Schulte L, Scheiner B, Voigtländer T, et al. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver Int, 2019, 39(1):714-726.
[4] El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists' review. World J Gastroenterol, 2019, 25(14):1653-1665.
[5] Wang YD, Pan T, Li L, et al. Benzo(a)pyrene promotes Hep-G2 cell migration and invasion by up regulating phosphorylated extracellular signal-regulated kinase expression. Oncol Lett, 2018, 15(6):8325-8332.
[6] 贺艳平, 李江怀. 内质网应激蛋白激酶R样内质网激酶/真核起始因子2α/转录激活因子6通路与大鼠肝癌细胞增殖及迁移的关系. 中华实验外科杂志, 2019, 36(10):1748-1751.
[7] Sirohi K, Verma M, Michalec L, et al. Chromoboxprotein-7 (CBX7), a polycomb group repressor, functions as a transcriptional co-activator of type 2 cytokine genes in lymphoid cells and is important for asthma. J All Clinil Imm, 2019, 143(2):183-187.
[8] 管振坡, 谷连坤, 邢宝才, 等. 色素框同源蛋白7基因在人体多种癌组织中表达下调. 中华预防医学杂志, 2011, 45(7):597-600.
[9] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015,7(21):151.
[10] Quinn C, Rakha EA. Eighthedition cancer staging manual of breast cancer by the American Joint Committee on Cancer: are the new changes to improve staging or a treatment decision tool? J Clin Pathol, 2018, 71(11):1028-1029.
[11] 郭立文, 邵国良. Hippo-YAP/TAZ信号通路在原发性肝癌中的研究进展. 中华肝脏病杂志, 2017, 25(11):878-880.
[12] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1):7-34.
[13] 杨继春, 于树青, 高乐, 等. 全球肝癌筛查指南制订现状的系统综述. 中华流行病学杂志, 2020, 41(7):1126-1137.
[14] Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. Cell, 2009, 136(2):200-206.
[15] 顾世玉, 秦文举, 高建芝, 等.肝细胞癌癌组织Hic-5和COL1A1表达及其对术后生存的预测价值. 实用肝脏病杂志, 2020, 23(4):576-580.
[16] Zhang XW, Zhang L, Wei Q, et al. Oncogenic role of the chromobox protein CBX7 in gastric cancer. J Exp Clin Cancer Res, 2010, 29(1):1-7.
[17] Zhu X, Qin M, Li C, et al. Downregulated expression of chromobox homolog 7 in hepatocellular carcinoma. Genet Test Mol Bioma, 2019, 23(5):348-352.
[18] Ni SJ, Zhao LQ, Wang XF, et al. CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways. J Hematol Oncol, 2018, 11(1):17.
[19] Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology, 2018, 68(4):1308-1318.
[20] Jin ZL, Yan W, Qu M, et al. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells. Exp Ther Med, 2018, 15(5):15046-5050.

肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响^*

Expression of CBX7 and PERK incancerous tissues in patients with hepatocellular carcinoma and its implication of prognosis after hepatectomy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[2]	于雷, 孙超, 张曼旭. 灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用^*[J]. 实用肝脏病杂志, 2021, 24(4): 476-479.
[3]	鲁小龙, 解春宝. IL-6基因多态性对HBV相关ACLF患者短期预后的影响[J]. 实用肝脏病杂志, 2021, 24(4): 516-519.
[4]	金苏素, 颜华东. 血清肾上腺髓质素前体诊断失代偿期肝硬化并发细菌感染及其预测短期预后的价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 528-531.
[5]	张兵, 陈瑞红, 杨威, 徐刚. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 548-551.
[6]	于哲, 罗婧, 杨永平. 外周血单个核细胞GPSM2水平可能是肝细胞癌预后判断的新型标志物^*[J]. 实用肝脏病杂志, 2021, 24(4): 556-560.
[7]	高金龙, 王海峰, 李娜, 梁朝晖, 张文正. 自MR-T2图像勾画肝细胞癌患者放疗靶区精度研究[J]. 实用肝脏病杂志, 2021, 24(4): 565-568.
[8]	于涛, 李奎武, 姚琳, 吕武. 胆囊癌患者胆囊癌组织泛素结合酶E2T蛋白表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 593-596.
[9]	王梦雨, 杨蕊旭, 范建高. 重视代谢相关脂肪性肝病的特征与预后临床研究^*[J]. 实用肝脏病杂志, 2021, 24(3): 308-311.
[10]	陈晨, 王联发, 王艳, 唐郡, 张骏飞, 黄猛珣, 刘波. 112例新型冠状病毒肺炎患者肝肾功能和心肌酶学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 351-354.
[11]	刘松涛, 孟庆华, 闾军, 刘梅, 许媛, 周建新, 胡中杰. 淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析[J]. 实用肝脏病杂志, 2021, 24(3): 383-386.
[12]	孔雪杰, 李江, 李昊天, 李绪桐, 郜玉峰. 不同肝病基础的慢加急性肝衰竭患者临床特征和预后评分模型预测效能比较[J]. 实用肝脏病杂志, 2021, 24(3): 387-390.
[13]	苏亚勇, 徐成润, 郭永木, 张惠勇, 刘双平, 陈小兰. 慢加急性乙型肝炎肝衰竭患者死亡危险因素和预后评分模型的构建[J]. 实用肝脏病杂志, 2021, 24(3): 391-394.
[14]	党玲, 贾皑, 王芳. 血清内毒素结合蛋白和sCD163水平预测亚急性肝衰竭患者预后的价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 447-448.
[15]	张维娜, 丁传刚, 赵红英, 李丽, 张曼军, 卢旭. 巨细胞病毒性肝炎患儿血清IFN-γ和IL-18水平变化及其与预后的关系探讨[J]. 实用肝脏病杂志, 2021, 24(2): 208-211.